Angelo Kent, Dalhaug Astrid, Pawinski Adam, Haukland Ellinor, Nieder Carsten
Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway.
Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway ; Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
ISRN Oncol. 2014 Mar 19;2014:912865. doi: 10.1155/2014/912865. eCollection 2014.
Purpose. Validation of a Canadian three-tiered prognostic model (survival prediction score, SPS) in Norwegian cancer patients referred for palliative radiotherapy (PRT), and evaluation of age-dependent performance of the model. Patients and Methods. We analyzed all 579 PRT courses administered at a dedicated PRT facility between 20.06.07 and 31.12.2009. SPS was assigned as originally described, That is, by taking into consideration three variables: primary cancer type, site of metastases, and performance status. Results. Patients with poor prognosis (non-breast cancer, metastases other than bone, and Karnofsky performance status (KPS) ≤ 60) had median survival of 13 weeks. Those with intermediate prognosis (two of these parameters) survived for a median of 29 weeks, and patients with good prognosis for a median of 114 weeks, P < 0.001. While this model performed well in patients who were 60 years or older, it was less satisfactory in younger patients (no significant difference between the good and intermediate prognosis groups). Conclusion. SPS should mainly be used to predict survival of elderly cancer patients. However, even in this group accuracy is limited because the good prognosis group contained patients with short survival, while the poor prognosis group contained long-term survivors. Thus, improved models should be developed.
目的。在挪威接受姑息性放疗(PRT)的癌症患者中验证加拿大三层预后模型(生存预测评分,SPS),并评估该模型的年龄依赖性表现。患者与方法。我们分析了2007年6月20日至2009年12月31日期间在一家专门的PRT机构进行的所有579次PRT疗程。SPS按照最初描述的方式进行赋值,即考虑三个变量:原发癌类型、转移部位和体能状态。结果。预后较差的患者(非乳腺癌、骨外转移以及卡诺夫斯基体能状态(KPS)≤60)的中位生存期为13周。预后中等的患者(这三个参数中有两个)中位生存期为29周,预后良好的患者中位生存期为114周,P<0.001。虽然该模型在60岁及以上患者中表现良好,但在年轻患者中效果较差(预后良好组和中等预后组之间无显著差异)。结论。SPS主要应用于预测老年癌症患者的生存情况。然而,即使在这组患者中,准确性也有限,因为预后良好组包含生存期短的患者,而预后较差组包含长期存活者。因此,应开发改进的模型。